Business Wire (Tue, 9:52AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,473 people get STJ articles and Market Currents by email alert.
Get email alerts on STJ »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
Business Wire (Tue, 8:00AM)
-
-
-
-
Business Wire (May 8, 2013)
-
-
Business Wire (May 3, 2013)
-
Business Wire (May 2, 2013)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 30, 2013)
-
-
Business Wire (Apr 17, 2013)
-
Business Wire (Apr 4, 2013)
-
5 Cheap Dividend Stocks Worth InvestigatingMarshall Hargrave • Tue, Mar 26
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
Boston Scientific Could Benefit From St. Jude Medical's TroublesTrefis • Tue, Nov 27, 2012 -
-
-
Why St. Jude Is Poised To Become A Solid Income StockValuentum • Thu, Sep 20, 2012 -
St. Jude Medical's Weaker Guidance Presents Another OpportunityStephen Simpson • Wed, Jul 18, 2012
-
-
-
-
-
-
St. Jude Medical: Earnings PreviewZacks Investment Research • Wed, Jan 25, 2012
-
Quality, With A Dividend, Now On Sale: St. Jude MedicalK202 • Tue, Jan 10, 2012 -
St. Jude Remains On Our Dividend Growth Watch ListValuentum • Wed, Jan 4, 2012
-
-
St. Jude: Earnings PreviewZacks Investment Research • Wed, Oct 19, 2011
-
-
-
-
5 Cheap Dividend Stocks Worth InvestigatingMarshall Hargrave • Tue, Mar 26
-
-
-
-
-
-
Fortune Could Favor A Bolder TerumoStephen Simpson • Thu, Feb 21
-
-
-
-
-
-
-
-
Checking The Pulse Of Healthcare StocksStock Traders Daily • Tue, Jan 22
-
-
-
St. Jude Medical Inc. - Analyst/Investor DayFri, Feb 3, 2012
-
St. Jude Medical Q2 2010 Earnings Call TranscriptThu, Jul 22, 2010
-
St. Jude Medical Inc. Q1 2010 Earnings Call TranscriptWed, Apr 21, 2010
-
St. Jude Medical Inc. Q4 2009 Earnings Call TranscriptWed, Jan 27, 2010
-
St. Jude Medical Inc., Q3 2009 Earnings Call TranscriptWed, Oct 21, 2009
-
St. Jude Medical, Inc. Q2 2009 Earnings Call TranscriptWed, Jul 22, 2009
-
St. Jude Medical, Inc. Q1 2009 Earnings Call TranscriptWed, Apr 22, 2009 • 1 Comment
-
St. Jude Medical Inc. Q4 2008 Earnings Call TranscriptTue, Jan 27, 2009
-
Business Wire (Tue, 8:00AM)
-
Business Wire (May 8, 2013)
-
Business Wire (May 3, 2013)
-
Business Wire (May 2, 2013)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 30, 2013)
-
Business Wire (Apr 17, 2013)
-
at CNBC.com (Apr 14, 2013)
-
at CNBC.com (Apr 9, 2013)
-
Business Wire (Apr 4, 2013)
-
Business Wire (Mar 21, 2013)
-
Business Wire (Mar 20, 2013)
-
Business Wire (Mar 11, 2013)
STJ vs. ETF Alternatives
Company Description
St. Jude Medical, Inc. develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiology and cardiac surgery and atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain. Our four operating... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, January 16, 10:02 AM The FDA approves St Jude's (STJ -1.9%) next-generation Merlin.net Patient Care Network (PCN), a system for cardiac patients with implanted medical devices that allows doctors to monitor them via the Internet and "detect heart failure symptoms earlier than ever before." Information is sent to doctors via the "Merlin@home" Transmitter and a patient's Internet connection. (PR) Comment! [Healthcare]
- Tuesday, January 15, 2:22 PM Boston Scientific (BSX +2.5%) hits a 16-month high today after Credit Suisse upped the stock to Outperform, citing a better top-line and improved visibility. On those catalysts, the firm reduces the valuation discount it thinks the stock should trade at versus rivals St. Jude (STJ) and Medtronic (MDT) to 10%. The stock currently trades at around a 20% discount to its peers. Comment! [Healthcare, On the Move]
- Tuesday, January 15, 8:46 AM The FDA has sent St Jude Medical (STJ) a warning about defects at the company's factory in California where it makes heart defibrillators, the wires for which have had no end of problems. The FDA won't authorize new product lines at the facility until the faults have been corrected but it's not seeking any product recalls or a shutdown of operations. St Jude doesn't expect the warning to hurt its earnings. Comment! [Healthcare]
- Wednesday, January 9, 5:43 PM St. Jude Medical (STJ) raises its preliminary Q4 results, now expecting an EPS of around $0.90 - $0.92, up from its prior view of $0.86 - $0.88 and better than Street estimates of $0.87. The firm cites better sales results along with cost savings initiatives during the quarter. Q4 sales are approximately $1.372B, slightly better than consensus estimates of $1.37B. Comment! [Earnings]
- Wednesday, January 9, 10:07 AM St. Jude Medical (STJ +0.2%) has reportedly pledged to improve training and quality procedures, and correct flaws the FDA found during an inspection of the company's Sylmar facility in California, which manufactures a key heart-rhythm device. The inspection focused on the Durata wires that connect defibrillators to the heart and which have had no end of problems. Comment! [Healthcare]
- Wednesday, January 9, 3:46 AM Volcano (VOLC) CEO Scott Huennekens has predicted that the market for a test that shows whether patients need heart stents could increase ten-fold to $2B within a decade. That would be a boon not only to Volcano, which sells the tests and could become a takeover target, but also to St. Jude Medical (STJ), which is the only other company in the game. Doctors are enthusiastic as data indicates they've been over-stenting. Comment! [Healthcare]
- Tuesday, December 11, 2012, 4:37 PM St. Jude Medical (STJ) declares $0.23/share quarterly dividend, in line with previous. Forward yield 2.60%. For shareholders of record Dec. 31. Payable Jan. 31. Ex-div date Dec. 27. (PR) Comment! [Dividends]
- Monday, December 10, 2012, 3:40 PM A group of Democratic Senators have signed a letter urging for a delay in implementing a tax on the medical device industry that is scheduled to go into effect January 1, saying the industry has received little guidance about how to comply with the tax, and is causing significant uncertainty and confusion. The Senators are requesting that a delay be included in the fiscal cliff bill Congress is currently negotiating. 2 Comments
- Thursday, December 6, 2012, 1:04 PM St. Jude Medical (STJ -0.5%) slips on a downgrade by TheStreet Ratings to Hold. The firm says that the stock's reasonable valuations are more than offset by deteriorating net income, weak operating cash flow and disappointing return on equity. Comment! [Healthcare]
- Friday, November 30, 2012, 11:27 AM St. Jude Medical (STJ +1.4%) gains on the back of yesterday's $1B buyback announcement and an upgrade to Buy at Mizuho. The firm says that concerns about a Durata recall are overblown, and that any impact on its EPS from market share loss in implanted defibrillators should be "more than offset" by yesterday's buyback announcement. Comment! [Healthcare, On the Move]
- Thursday, November 29, 2012, 4:41 PM Maybe seeing value after a 12% post-election tumble in the stock, St. Jude Medical's (STJ) board authorizes a share repurchase of up to $1B, roughly 10% of the float. Shares +1.1% AH. (PR) Comment! [Healthcare]
- Monday, November 26, 2012, 11:01 AM Boston Scientific (BSX +2.7%) bucks a down tape this morning on an upgrade to Buy at Citigroup. The firm says BSX is positioned to be the biggest winner from St. Jude Medical's (STJ -1%) Durata troubles. Citi expects it will be taken off the market within six months, and the ripple effects are likely to cost STJ around $820M in annual sales. BSX could easily take 41% of that market share, with Medtronic (MDT -0.9%) absorbing around 29%. Citi's upgrade differs widely from comments made on Friday by BofA Merrill, which put the risk of a Durata recall well below 50%. Comment! [Healthcare, On the Move]
- Monday, November 26, 2012, 10:49 AM St. Jude Medical (STJ -1%) says the first patient implant using its Portico Transcatheter heart valve has been made, using a Transapical Delivery System. The Portico Transcatheter heart valve is made of bovine pericardial tissue and is designed to increase physicians' control and placement accuracy during valve deployment. The valve has the ability to be completely re-sheathed and repositioned, which allows the physician to retrieve the valve, if necessary. Comment! [Healthcare]
- Friday, November 23, 2012, 11:50 AM Shares of St. Jude Medical (STJ +3%) claw back a bit of their 12% pummeling taken on Wednesday following the FDA's release of a report citing serious flaws in STJ's oversight of Durata. BofA Merrill Lynch notes that the report found no new safety issues and the probability of a recall stands well below 50%, which is already priced into the stock. It reiterates a Buy with a potential downside to $24 and an upside peaking around $40. Comment! [Healthcare, On the Move]
- Wednesday, November 21, 2012, 12:45 PM Midday top 10 gainers: MEMS +72%. NLP +38%. ARCI +20%. INFI +14%. VVUS +14%. NCTY +13%. SKX +12%. SQNM +11%. PSUN +11%. MTSL +11%. Midday top 10 Losers: STV -46%. ZLC -29%. CNET -18%. SCHL -18%. TLYS -17%. STJ -14%. CLNT -13%. EBR -11%. HGSH -11%. KID -11%. 1 Comment [On the Move]
- Tuesday, November 20, 2012, 7:35 PM A recent FDA report cites serious flaws in St. Jude Medical's oversight of design changes made to its Durata line of devices. Earlier this year, STJ had released a heavily redacted version of the FDA's report, but the recent release of the same report by the FDA shows highlights a pattern of inadequate verification and flawed testing procedures that could renew concerns over the safety of the Durata device. Shares -0.3% AH. Comment! [Healthcare]
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Ryan Mallory
Short Side Swing-Trading Watch-List | $YOKU $STJ & $CZZ are my favs right now http://bit.ly/TjnLh5 - View all 0 replies
-
Rancodemayor
$STJ down 5.26 points or 14.7%, trading at $30.45, following issue reported with it's implanted defibrillator. The share continues to slide. - View all 0 replies
-
Alan Brochstein
$STJ looks to be holding key support after an overreaction to a potential warning letter - View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
-
Alan Brochstein
$STJ restructuring wasn't because biz got worse - it's due to pending medical device tax - View all 0 replies
-
Alan Brochstein
$STJ restructuring wasn't because biz got worse - it's due to pending medical device tax - View all 0 replies
LATEST REPLIES